TEPANIL TEN-TAB (diethylpropion hydrochloride) by Teva is clinical pharmacology diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity, higher. First approved in 1977.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
TEPANIL TEN-TAB (diethylpropion hydrochloride) is a sympathomimetic amine oral extended-release tablet approved in 1977 for management of exogenous obesity. It works through central nervous system stimulation and appetite suppression, enabling patients on dietary management to achieve modest weight loss averaging a fraction of a pound per week.
Product approaches loss of exclusivity with moderate competitive pressure (30/100); team may transition toward generic optimization or end-of-life planning.
CLINICAL PHARMACOLOGY Diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Actions include some central nervous system stimulation and elevation of blood pressure. Tolerance…
Worked on TEPANIL TEN-TAB at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TEPANIL TEN-TAB offers limited career upside due to approaching LOE, minimal clinical pipeline, and intense generic competition in a declining therapeutic category. Career value lies primarily in generic transition planning, supply chain optimization, or regulatory wind-down activities.